A phase I trial of Flavopiridol in relapsed multiple myeloma

PURPOSE: Flavopiridol is primarily a cyclin-dependent kinase (CDK)-9 inhibitor and we performed a dose escalation trial to determine the maximum tolerated dose, safety, and generate a pharmacokinetic profile. METHODS: Patients with a diagnosis of relapsed myeloma after at least two prior treatments...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hofmeister, Craig C., Poi, Ming, Bowers, Mindy A., Zhao, Weiqiang, Phelps, Mitch A., Benson, Don M., Kraut, Eric H., Farag, Sherif, Efebera, Yvonne A., Sexton, Jennifer, Lin, Thomas S., Grever, Michael, Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3946636/
https://ncbi.nlm.nih.gov/pubmed/24241210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2347-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados